Earnings digests and industry comparisons for Japan's biggest listed companies.
640 reports(page 15 of 54)
Sanyo Shokai reported a widening operating loss of 499 million yen for the second quarter of FY2027, ending in August. Sales dropped 4.0% to 25.95 billion yen as polarization in consumer spending pressured revenues, though cost-cutting measures remain a strategic priority.
FY2027 Q2 (Mar-Aug 2026)
Pal Group reported H1 FY2027 results on Oct 6, 2026, with revenue reaching 121.93 billion yen, a 4.1% increase year-over-year. This growth was driven by the apparel segment and EC expansion, though profit margins faced pressure.
H1 FY2027 (Aug-Sep 2026)
Tosei reported strong third-quarter results for the fiscal year ending November 2026, driven by its property regeneration business. Revenue and operating profit rose significantly, enabling the company to raise its full-year forecast and increase dividends.
FY2026 Q3 (Jul-Sep)
Nextage reported its third-quarter results for fiscal 2026 with revenue of ¥600,422 million (up 26.0% year on year), operating profit of ¥21,624 million (up 66.7%), and net income attributable to owners of ¥13,845 million (up 74.9%). Strong used-car demand and buy-only store openings lifted progress to 80.5% of the full-year revenue target and 78.3% of the operating profit target.
FY2026 Q3 (Dec 2025 to Aug 2026)
Create SD reported a 6.5% increase in first-quarter revenue for the fiscal year ending May 2027, reaching 129.54 billion yen. However, rising input costs and adverse weather conditions pressured profits, resulting in a decline in operating income.
Q1 FY2027 (Jun-Aug 2026)
Rohto revised its fiscal year 2030 sales target up by 29 billion yen to 444 billion yen. The company is also adopting rolling forecasts instead of fixed targets through 2031.
Property renewal leader Tosei has revised its full-year forecast for the fiscal year ending November 2026, raising operating profit significantly while increasing the final dividend to 58 yen. Although sales revenue is expected to decline, improved margins and enhanced shareholder returns underscore a strategic pivot toward higher value.
Shionogi will acquire US biotech IntraBio for $2 billion, securing global rights to the rare disease drug AQNEURSA. This strategic move establishes a new high-value revenue pillar alongside its infectious disease business.
Kansai Electric will raise basic charges for low-voltage customers in the capital region by approximately 29% starting November 1. The adjustment reflects transmission fees and signals a shift toward higher fixed costs. This move pushes rates above industry norms as the utility seeks cost recovery.
Takara Holdings announced it will transfer a 70% stake in Takara Logistics Systems to Central Warehouse on Oct 5, 2026. This move aligns with its strategy to focus resources on core alcohol business operations.
Nihon M&A Center disclosed that its mid-term dividend for the fiscal year ending March 2026 exceeded the legal distributable amount by approximately 833 million yen. The company stated it will not demand repayment from shareholders and is establishing a third-party committee to investigate the internal control failure.
Otsuka Holdings subsidiary Daikochi Kogyo has started the New Drug Application process for its lung cancer drug Zeprelertinib in the United States. The company aims to complete the application by late 2026, leveraging an expedited review program to potentially accelerate market entry.
